Home Cart Sign in  
Chemical Structure| 475205-49-3 Chemical Structure| 475205-49-3

Structure of A-317491
CAS No.: 475205-49-3

Chemical Structure| 475205-49-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A-317491 is a potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors with Ki values of 22 nM and 9 nM for human P2X3 and P2X2/3 receptors.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A-317491

CAS No. :475205-49-3
Formula : C33H27NO8
M.W : 565.57
SMILES Code : O=C(C1=CC(C(N(CC2=CC=CC(OC3=CC=CC=C3)=C2)[C@H]4CCCC5=C4C=CC=C5)=O)=C(C(O)=O)C=C1C(O)=O)O
MDL No. :MFCD28044314
InChI Key :VQGBOYBIENNKMI-LJAQVGFWSA-N
Pubchem ID :9829395

Safety of A-317491

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
A-317491 exhibits high efficacy and selectivity as a non-nucleotide P2X3 and P2X2/3 receptor blocker, presenting Kis of 22, 22, 9, and 92 nM against hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. Its selective action (IC50>10 μM) spans beyond other P2 receptors and a range of neurotransmitter receptors, ion channels, and enzymes, mitigating inflammatory and neuropathic pain by obstructing P2X3 and P2X2/3 receptor-mediated calcium movement .
Target
  • P2X receptor

    Rat P2X2/3, Ki:92 nM

    Human P2X3, Ki:22 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat dorsal root ganglion neurons 15 nM 3 minutes To evaluate the antagonistic effects of A-317491 on native P2X3 receptors, results showed that A-317491 effectively blocked currents in these receptors PMC139289
1321N1 human astrocytoma cells 22–92 nM 3 minutes To evaluate the antagonistic effects of A-317491 on P2X3 and P2X2/3 receptors, results showed that A-317491 effectively blocked calcium flux in these receptors PMC139289
1321N1 human astrocytoma cells expressing hP2X2/3 1.3–660 nM 2–5 hours To determine the affinity of AF-353 for P2X2/3 receptors PMC2938810
CHO-K1 cells expressing recombinant human P2X3 1.7–140 nM 2–5 hours To determine the affinity of AF-353 for P2X3 receptors PMC2938810
1321N1 cells 3 nM 30 minutes To assess whether naloxone could compete for binding to human P2X3 receptors. Results showed that naloxone, at concentrations up to 1 μM, did not compete for [3H] A-317491 binding. PMC1576275
NG108-15 cells 3–100 μM To evaluate the agonist activity of A-317491 at δ opioid receptors endogenously expressed in NG108-15 cells. Results showed that A-317491 did not produce any agonist response at the tested concentrations. PMC1576275
1321N1 astrocytoma cells 12.5–500 nM To investigate the competitive antagonism of A-317491 on the P2X2/C03 chimeric receptor, results showed that A-317491 is a potent competitive antagonist with a pA2 value of 52.1 nM. PMC1574009
Rat dorsal root ganglion (DRG) neurons 20 μM To investigate the effect of miR-1306-3p on action potentials in DRG neurons, results showed that A317491 significantly inhibited miR-1306-3p-induced inward currents and action potentials. PMC10281022

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Xenopus oocytes Xenopus oocytes Injection 2 µM Single injection, lasting 1-2 days To evaluate the inhibitory effect of A-317491 on ATP-induced currents PMC5161641
Rat Chronic constriction injury model Subcutaneous injection 10–15 μmol/kg Single or multiple dosing To evaluate the analgesic effects of A-317491 in chronic pain models, results showed that A-317491 significantly reduced thermal hyperalgesia and mechanical allodynia PMC139289
Sprague-Dawley rats Chronic inflammatory thermal hyperalgesia (CFA), acute inflammatory thermal hyperalgesia (carrageenan), neuropathic pain models (CCI and L5-L6 nerve ligation), formalin- and α,β-meATP-induced nociception models Intrathecal and intraplantar injections 1-500 nmol (intrathecal and intraplantar injections) Intrathecal injections 5 min before testing, intraplantar injections 30 min before testing To evaluate the antinociceptive effects of A-317491 in various acute and chronic pain models. Results showed that intrathecal and intraplantar injections of A-317491 significantly reduced thermal hyperalgesia in the CFA model, intrathecal administration significantly attenuated mechanical allodynia in neuropathic pain models, and both routes significantly reduced nocifensive behaviors in the formalin model. PMC1574160
Hanover Wistar rats Hanover Wistar rats Intravenous and oral 2 mg/kg Single dose To evaluate the pharmacokinetic parameters of AF-353. PMC2938810
Sprague-Dawley rats CFA-induced chronic thermal hyperalgesia model, formalin model, L5–L6 nerve ligation model Subcutaneous injection 1–300 μmol/kg Single administration, testing started 30 min after administration To evaluate the antinociceptive effects of A-317491 in inflammatory and chemogenic pain models. Results showed that naloxone (1–10 mg/kg, i.p.) dose-dependently reduced the antinociceptive effects of A-317491 in the CFA thermal hyperalgesia model and formalin model but not in the L5–L6 nerve ligation model. PMC1576275
Rats CFA-induced inflammatory pain model Subcutaneous injection 3, 10, 30 mg/kg Single dose, observed for 1 hour Evaluate the analgesic effect of A-317491 analogs in an inflammatory pain model, results showed compound B significantly reversed CFA-induced weight bearing deficit at 3 and 10 mg·kg-1 doses PMC3144543
Rats Chronic constriction injury (CCI) model Intravenous injection 1, 3, 10 mg/kg Cumulative dosing, each dose observed for 45 minutes To investigate the effects of A-317491 on neuronal responses in a neuropathic pain model. Results showed that in CCI-operated rats, 3 mg/kg A-317491 significantly inhibited C fibre-evoked responses, and 10 mg/kg significantly inhibited Aδ and C fibre-evoked responses. PMC1617075
Sprague-Dawley (SD) rats Chronic visceral pain model Intrathecal injection 10 μM/10 mL Single injection To investigate the inhibitory effect of A-317491 on miR-1306-3p-induced visceral pain, results showed that A-317491 significantly alleviated chronic visceral pain. PMC10281022
Sprague-Dawley rats Chronic morphine-induced analgesic tolerance model Intrathecal injection 15 μg Once daily for 7 days To evaluate the effect of A-317491 on chronic morphine-induced analgesic tolerance. Results showed that A-317491 significantly attenuated the loss of morphine’s analgesic potency. PMC5913404
Suncus murinus (house musk shrews) Emesis model Intraperitoneal injection 100 mg/kg Single administration, observed for 60 minutes To investigate the inhibitory effect of A-317491 on α,β-meATP-induced emetic responses, results showed complete inhibition at 100 mg/kg dose. PMC2050822

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.84mL

1.77mL

0.88mL

17.68mL

3.54mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories